logo
  

Solazyme Receives GRAS No Questions Letter From FDA For High Oleic Algae Oil

Solazyme, Inc. (SZYM), a renewable oil and ingredients company, said the U.S. Food and Drug Administration has issued a favorable response to Solazyme's notification which concludes that high-oleic algae oil is Generally Recognized as Safe or GRAS as an ingredient in food products under the intended conditions of use.

According to the company, this No Questions letter will pave the way for mainstream adoption of superior quality oleic algae oil with unprecedented functional, performance and nutritional benefits, enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients.

Solazyme said its portfolio of high oleic algae oils are unique in that they can offer an unprecedented amount of healthy monounsaturated fat (omega-9s), and 0g trans fat with exceptional stability and low levels of saturated fat. They have a very light color and neutral flavor allowing the flavor of foods to come through in recipes.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT